DICK’S Sporting Goods plunged roughly 30% as Foot Locker weakness rattled Wall Street. Then three directors bought $2.94 million. With core DICK’S comps up 4.9%, operating cash flow at $792 million and the stock at 9.3x forward earnings, is Wall Street pricing temporary integration pain like permanent deterioration?

Read entire article

NGL Energy Partners director John Raymond just put $5.1 million behind the turnaround. With record Permian water volumes, rising EBITDA and heavy institutional ownership, NGL looks increasingly compelling—but leverage keeps our FunStock Index at 7.95/10.

Read entire article

Kura Oncology is evolving from a clinical-stage biotech into a commercial oncology company. With KOMZIFTI gaining traction, over $500 million in cash, strong institutional ownership and multiple Phase 3 catalysts ahead, is KURA becoming one of biotech's most compelling long-term opportunities?

Read entire article

Medifast (NYSE: MED) has nearly $170 million in cash, no debt, insider buying and a bold strategic pivot through Trilivy. But shrinking revenues and GLP-1 competition still cast a long shadow. Here's the complete bull vs. bear case.

Read entire article

SiteOne Landscape Supply isn't flashy—but it may be one of the market's most overlooked industrial compounders. After a sharp correction, CEO Doug Black invested more than $816,000 of his own money while institutions continue to dominate the shareholder base. We examine the valuation, competitive moat, earnings, risks, and whether this roll-up story deserves another look.

Read entire article

Bunge isn't merely a grain trader—it's one of the world's most important agricultural infrastructure companies. After a 43% rally from our 2025 recommendation, a healthy pullback, another insider purchase, stronger earnings guidance and accelerating Viterra synergies make the long-term investment story compelling once again.

Read entire article

Huntsman isn't simply a cyclical chemical company anymore. Between repeated insider buying, a transformational $12.5 billion merger with Olin, trading at just 0.64x book value and more than $400 million in projected synergies, investors may be looking at one of the market's more intriguing industrial turnaround opportunities.

Read entire article

Albertsons has disappointed Wall Street—but one executive just invested nearly $2 million of his own money. We examine the insider buy, valuation, operating cash flow, ACI Edge restructuring, dividend sustainability and whether ACI could become one of the market's more interesting turnaround stories.

Read entire article

Conagra's 50% dividend cut shocked income investors—but the story didn't end there. With CEO John Brase buying more than $510,000 of stock, debt moving lower, and shares trading around 10x forward earnings, the turnaround thesis deserves another look.

Read entire article

Standard Nuclear may help power tomorrow's AI-driven economy, but investing isn't about buying exciting technologies at any price. We examine STDN's IPO, Decisive Point's $19 million purchase, its impressive backlog, and why patience may be the smartest move.

Read entire article